Literature DB >> 26949052

A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth.

Yijian Zhang1, Shibo Liu1, Lei Wang1, Yaoshi Wu2, Jiaqi Hao1, Zheng Wang1, Wei Lu1, Xu-An Wang1, Fei Zhang1, Yang Cao1, Haibin Liang1, Huaifeng Li1, Yuanyuan Ye1, Qiang Ma1, Shuai Zhao1, Yijun Shu1, Runfa Bao1, Lin Jiang1, Yunping Hu1, Jian Zhou1, Lei Chen3, Yingbin Liu4.   

Abstract

Nectin-4 is a Ca(2+)-independent immunoglobulin-like cell adhesion molecule which has diverse functions in cell-cell adhesion via homophilic and heterophilic interactions. Cell-cell adhesive processes are central to cell polarization, differentiation, proliferation, survival and movement. Here we report that Nectin-4 is substantially overexpressed in gallbladder cancer (GBC), the most common biliary tract malignancy with a high risk of local tumor spread and invasion. Further, Nectin-4 high expression in GBC patients was associated with pathologic T stage and lymph node metastasis status, and the expression level of the downstream target Rac1 and poor prognoses were also correlated with Nectin-4. Ectopic expression of Nectin-4 promoted GBC cell growth, motility and tumor growth in a mouse model. The depletion of Nectin-4 inhibited GBC cell proliferation and migration both in cell culture and in mice. Our data suggest that activation of the PI3K/AKT pathway was involved in the oncogenic function of Nectin-4 to activate Rac1 in GBC. Inhibition of PI3K/AKT with LY294002 and/or Rac1 with NSC23766 impaired Nectin-4-mediated GBC cell proliferation and motility. We hypothesize that Nectin-4 is critical for GBC progression via PI3K/AKT pathway activation of Rac1. Nectin-4 may be a novel prognostic factor and therapeutic target in GBC patients.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gallbladder cancer; Nectin-4; PI3K/AKT pathway; Rac1; Tumor progression

Mesh:

Substances:

Year:  2016        PMID: 26949052     DOI: 10.1016/j.canlet.2016.02.049

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  30 in total

1.  Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse.

Authors:  Chinmayee Sethy; Kunal Goutam; Deepika Nayak; Rajalaxmi Pradhan; Sefinew Molla; Subhajit Chatterjee; Niranjan Rout; Michael D Wyatt; Satya Narayan; Chanakya Nath Kundu
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

2.  Diallyl trisulfide regulates cell apoptosis and invasion in human osteosarcoma U2OS cells through regulating PI3K/AKT/GSK3β signaling pathway.

Authors:  Pan He; Zhijun Wang; Bin Sheng; Yongqiang Xu; Siyin Feng; Yan Huang; Fuqiang Gong; Liting Tang; Liming Xie
Journal:  Histol Histopathol       Date:  2020-12-29       Impact factor: 2.303

3.  High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer.

Authors:  Yan Zhang; Jiaxuan Zhang; Qin Shen; Wei Yin; Hua Huang; Yifei Liu; Qingfeng Ni
Journal:  Oncol Lett       Date:  2018-03-28       Impact factor: 2.967

Review 4.  The biology and rationale of targeting nectin-4 in urothelial carcinoma.

Authors:  Elisabeth I Heath; Jonathan E Rosenberg
Journal:  Nat Rev Urol       Date:  2020-11-25       Impact factor: 14.432

Review 5.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

Review 6.  Nectin-4: a Novel Therapeutic Target for Skin Cancers.

Authors:  Hiroki Hashimoto; Yuka Tanaka; Maho Murata; Takamichi Ito
Journal:  Curr Treat Options Oncol       Date:  2022-03-21

7.  Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation.

Authors:  Anmada Nayak; Sarita Das; Deepika Nayak; Chinmayee Sethy; Satya Narayan; Chanakya Nath Kundu
Journal:  Cell Oncol (Dordr)       Date:  2019-01-03       Impact factor: 6.730

8.  Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity.

Authors:  Zhao-Xiang Ren; Ya-Fei Zhao; Ting Cao; Xue-Chu Zhen
Journal:  Acta Pharmacol Sin       Date:  2016-07-04       Impact factor: 6.150

9.  Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.

Authors:  Thomas Powles; Jonathan E Rosenberg; Guru P Sonpavde; Yohann Loriot; Ignacio Durán; Jae-Lyun Lee; Nobuaki Matsubara; Christof Vulsteke; Daniel Castellano; Chunzhang Wu; Mary Campbell; Maria Matsangou; Daniel P Petrylak
Journal:  N Engl J Med       Date:  2021-02-12       Impact factor: 91.245

Review 10.  Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.

Authors:  Jeffrey L Wong; Jonathan E Rosenberg
Journal:  Expert Opin Biol Ther       Date:  2021-05-24       Impact factor: 5.589

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.